Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neoadjuvant immunotherapy trials in renal cell carcinoma (RCC).

Given the data seen in the metastatic space, the field is moving toward immunotherapy-based approaches, says Voss. This is especially true for preoperative trials in non-metastatic disease.

The phase III PROSPER RCC trial (NCT03055013) is comparing nephrectomy with or without nivolumab (Opdivo), and is currently accruing in the United States. 

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Genitourinary Cancers

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research. 

SUO Annual Meeting

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neoadjuvant immunotherapy trials in renal cell carcinoma (RCC).
 

Dr. Voss Discusses Neoadjuvant Trials of Immunotherapy in RCC